hairy cell leukemia

Clinical trial suggests moxetumomab pasudotox may be an effective treatment for hairy cell leukemia

Jun 15, 2018

Findings from a phase III international clinical trial, led by Robert Kreitman, M.D., Senior Investigator in the Laboratory of Molecular Biology (LMB), show moxetumomab pasudotox (Moxe) may be an effective treatment option for patients with relapsed or refractory hairy cell leukemia (HCL). Initially developed by an LMB team led by Ira Pastan, M.D., Moxe is a toxin-based drug that can eliminate tiny deposits of cancer cells hiding in bone marrow – referred to as minimal residual disease. These deposits often avoid being killed by standard chemotherapy and are thought to be the cause of relapsed HCL. According to Dr. Kreitman, Moxe offers an option for HCL patients to avoid additional chemotherapy and may potentially improve long-term outcomes.  Read more...

Clinical trial suggests moxetumomab pasudotox may be an effective treatment for hairy cell leukemia
Travis at The Children's Inn

Pediatric clinical trial supports use of selumetinib for children with neurofibromatosis type 1

Jun 15, 2018

Preliminary results from a phase II clinical trial at the Center for Cancer Research support the use of the investigational drug selumetinib for shrinking tumors in children and young adults with neurofibromatosis type 1 (NF1). NF1 is a genetic syndrome that often causes tumors, called plexiform neurofibromas, to develop in nerve cells on or under the skin. Although most of these tumors are not cancerous, patients commonly experience pain, reduced mobility and difficulty breathing. Results from the study, led by Brigitte Widemann, M.D., Chief of the Pediatric Oncology Branch, not only confirm findings from a smaller 2016 study demonstrating the drug’s ability to shrink large tumors, but also suggest the drug may improve symptoms. Read more...

Pediatric clinical trial supports use of selumetinib for children with neurofibromatosis type 1
Cell division in breast cancer

Committing to cell division may be clue to cancer cell growth

Jun 6, 2018

In a new study in Nature, CCR researchers describe, for the first time, how a cell commits to dividing during the cell cycle. Since cancer cells divide when they should not, targeting this pathway might stop their inappropriate growth. Read more...

Tumor cell

Antibody-linked drug shrinks various types of tumors in preclinical study

Jun 5, 2018

A preclinical study by Center for Cancer Research investigators and colleagues shows that a drug guided by an attached target-seeking antibody can recognize cells infiltrating tumors, the tumor stroma, and cause various types of tumors to shrink, and in many cases, disappear. Their findings suggest that when stromal cells take up the ADC, they cleave the drug from the antibody and release it to kill neighboring tumor cells. Read more...

gut bacteria

New study finds gut microbiome can control antitumor immune function in liver

May 24, 2018

Scientists led by Tim Greten, M.D., Deputy Chief of the Thoracic and GI Malignancies Branch, have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study published May 24, 2018, in Science and showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them. Read more...

New study finds gut microbiome can control antitumor immune function in liver
SIV

Selectively engaging immune responses may be key to fighting HIV infection

May 22, 2018

An infection-fighting white blood cell known as a CD14+ monocyte could be a key element in developing an effective human immunodeficiency virus (HIV) vaccine, according to a new finding published May 21, 2018, in Nature Medicine. The primate study was conducted at the Center for Cancer Research, NCI, and led by Genoveffa Franchini, M.D., Senior Investigator in the Vaccine Branch. Read more...

Liver cancer

Scientists develop potential new approach against cancer metastasis

May 16, 2018

A collaboration between the National Institutes of Health Intramural Research Program, Northwestern University and their collaborative research partners has identified a compound called metarrestin that blocks the spread of pancreatic and other cancers in animal models. Mice treated with metarrestin also had fewer tumors and lived longer than mice that did not receive treatment. The results of this study were published in Science Translational Medicine on May 16, 2018, and described in a press release from the NIH’s National Center for Advanicing Translational Sciences (NCATS).  Read more...

Scientists develop potential new approach against cancer metastasis
Blood cell

Activated platelets can promote tumor cell invasion into healthy tissue

Apr 19, 2018

Pre-clinical studies conducted by CCR investigators and colleagues show that platelets, tiny cells that promote blood clotting, when activated by the CD97 protein on the surface of tumor cells, enable the tumor cells to invade healthy tissue and then metastasize. The study, published April 17, 2018, in Cell Reports, was led by Kathleen Kelly, Ph.D., Chief, Laboratory of Genitourinary Cancer Pathogenesis. Read more...

Visual of mutations

Focusing on function to mine cancer genome data

Apr 17, 2018

CCR scientists have devised a strategy to sift through the tens of thousands of mutations in cancer genome data to find mutations that actually drive the disease. They have used the method to discover that the JNK signaling pathway, which in different contexts can either spur cancerous growth or rein it in, acts as a tumor suppressor in gastric cancers.  Read more...

Subgroups of DLBCL

Study led by Louis Staudt revises molecular classification for most common type of lymphoma

Apr 13, 2018

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. Though potentially curable, treatment does not eliminate the disease for all patients. A new study led by Louis Staudt, M.D., Co-Chief of the Lymphoid Malignancies Branch, identified genetic subtypes of DLBCL that could help explain why some patients respond to treatment whereas others do not.  Read more...

Study led by Louis Staudt revises molecular classification for most common type of lymphoma

Pages